Updated Jun 2, 2026
Upgrade to a paid plan to see AI rating history on the chart.
Why Insmed Stock Is Back on Investors’ Radar Insmed (INSM) has drawn fresh attention after a period of weaker share performance, with the stock down 20% over t…
As the first-to-market DPP-1 inhibitor, Brinsupri is on course to become the standard of care in bronchiectasis treatment.
MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth.
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeli…
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPcVNjYzZFMlA1X3lKNzRtc082Rnh3SUZrZ1Z4emJ3ZmJ1WEdyNVhrbllXd1RYdzBGNlZad3hoalllQm5oT25XRHZkYzN0QnpRN…
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “infle…
Not investment advice. Past performance does not guarantee future results. Full disclaimer